Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424. https://doi.org/10.1056/NEJMoa1606220

Article  PubMed  Google Scholar 

Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243–262. https://doi.org/10.1016/j.eururo.2020.09.042

Article  CAS  PubMed  Google Scholar 

Schaeffer E, An Y, Barocas D et al (2022) NCCN Guidelines Version 1.2023 Prostate Cancer. In: Available from: https://www.nccn.org/home/. Accessed 1 Mar 2023

Rodrigues G, Warde P, Pickles T et al (2012) Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 6:121–127. https://doi.org/10.5489/cuaj.11085

Article  PubMed  PubMed Central  Google Scholar 

Stolzenbach LF, Rosiello G, Pecoraro A et al (2020) Prostate cancer grade and stage misclassification in active surveillance candidates: Black versus White patients. J Natl Compr Canc Netw 18:1492–1499. https://doi.org/10.6004/jnccn.2020.7580

Article  PubMed  Google Scholar 

Yang DD, Mahal BA, Muralidhar V et al (2019) Risk of upgrading and upstaging among 10 000 patients with Gleason 3+4 favorable intermediate-risk prostate cancer. Eur Urol Focus 5:69–76. https://doi.org/10.1016/j.euf.2017.05.011

Article  PubMed  Google Scholar 

Daskivich TJ, Wood LN, Skarecky D et al (2017) Limitations of the National Comprehensive Cancer Network® (NCCN®) Guidelines for Prediction of Limited Life Expectancy in Men with Prostate Cancer. J Urol 197:356–362. https://doi.org/10.1016/j.juro.2016.08.096

Article  PubMed  Google Scholar 

Martin NE, Chen M-H, Zhang D et al (2017) Unfavorable intermediate-risk prostate cancer and the odds of upgrading to gleason 8 or higher at prostatectomy. Clin Genitourin Cancer 15:237–241. https://doi.org/10.1016/j.clgc.2016.06.001

Article  PubMed  Google Scholar 

Sorce G, Flammia RS, Hoeh B et al (2022) Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. Prostate 82:1040–1050. https://doi.org/10.1002/pros.24349

Article  CAS  PubMed  PubMed Central  Google Scholar 

Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40 244–252. https://doi.org/10.1097/PAS.0000000000000530

Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822. https://doi.org/10.1016/S0140-6736(16)32401-1

Article  PubMed  Google Scholar 

Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 69:16–40. https://doi.org/10.1016/j.eururo.2015.08.052

Article  PubMed  Google Scholar 

Wibmer AG, Chaim J, Lakhman Y et al (2021) Oncologic outcomes after localized prostate cancer treatment: associations with pretreatment prostate magnetic resonance imaging findings. J Urol 205:1055–1062. https://doi.org/10.1097/JU.0000000000001474

Article  PubMed  Google Scholar 

Hassanzadeh E, Glazer DI, Dunne RM et al (2017) Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdom Radiol (NY) 42:278–289. https://doi.org/10.1007/s00261-016-0871-z

Article  PubMed  Google Scholar 

Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777. https://doi.org/10.1056/NEJMoa1801993

Article  PubMed  PubMed Central  Google Scholar 

Algohary A, Viswanath S, Shiradkar R et al (2018) Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: preliminary findings. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25983

Article  PubMed  PubMed Central  Google Scholar 

Alessi S, Pricolo P, Summers P et al (2019) Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients. Eur Radiol 29:5478–5487. https://doi.org/10.1007/s00330-019-06092-0

Article  PubMed  PubMed Central  Google Scholar 

Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757. https://doi.org/10.1007/s00330-011-2377-y

Article  PubMed  PubMed Central  Google Scholar 

Chaddad A, Kucharczyk MJ, Niazi T (2018) Multimodal radiomic features for the predicting Gleason score of prostate cancer. Cancers (Basel) 10:E249. https://doi.org/10.3390/cancers10080249

Article  Google Scholar 

Mazzone E, Stabile A, Pellegrino F et al (2021) Positive predictive value of Prostate Imaging Reporting and Data System Version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 4:697–713. https://doi.org/10.1016/j.euo.2020.12.004

Article  PubMed  Google Scholar 

Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group: CANCER CONTROL RATES: COMPARISON OF TREATMENT OPTIONS. BJU Int 109:22–29. https://doi.org/10.1111/j.1464-410X.2011.10827.x

Article  PubMed  Google Scholar 

Artibani W, Porcaro AB, De Marco V et al (2018) Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int 100:251–262. https://doi.org/10.1159/000481438

Article  CAS  PubMed  Google Scholar 

Kornberg Z, Cooperberg MR, Spratt DE, Feng FY (2018) Genomic biomarkers in prostate cancer. Transl Androl Urol 7:459–471. https://doi.org/10.21037/tau.2018.06.02

Article  PubMed  PubMed Central  Google Scholar 

Eggener SE, Rumble RB, Beltran H (2020) Molecular biomarkers in localized prostate cancer: ASCO Guideline Summary. JCO Oncol Pract 16:340–343. https://doi.org/10.1200/JOP.19.00752

Article  PubMed  Google Scholar 

Gaudreau P-O, Stagg J, Soulières D, Saad F (2016) The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Biomark Cancer 8:15–33. https://doi.org/10.4137/BIC.S31802

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu M, Fang M, Zou J et al (2019) Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions. Eur J Radiol 114:38–44. https://doi.org/10.1016/j.ejrad.2019.02.032

Article  PubMed  Google Scholar 

Zhou Y, Yuan J, Xue C et al (2022) A pilot study of MRI radiomics for high-risk prostate cancer stratification in 1.5 T MR-guided radiotherapy. Magn Reson Med. https://doi.org/10.1002/mrm.29564

Gaudiano C, Mottola M, Bianchi L et al (2022) Beyond multiparametric MRI and towards radiomics to detect prostate cancer: a machine learning model to predict clinically significant lesions. Cancers (Basel) 14:6156. https://doi.org/10.3390/cancers14246156

Article  PubMed  Google Scholar 

Woźnicki P, Westhoff N, Huber T et al (2020) Multiparametric MRI for prostate cancer characterization: combined use of radiomics model with PI-RADS and clinical parameters. Cancers (Basel) 12:1767. https://doi.org/10.3390/cancers12071767

Article  PubMed  Google Scholar 

Zhang L, Zhe X, Tang M et al (2021) Predicting the grade of prostate cancer based on a biparametric MRI radiomics signature. Contrast Media Mol Imaging 2021:7830909. https://doi.org/10.1155/2021/7830909

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong D, Tang L, Li Z-Y et al (2019) Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol 30:431–438. https://doi.org/10.1093/annonc/mdz001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446. https://doi.org/10.1016/j.ejca.2011.11.036

Article  PubMed  PubMed Central  Google Scholar 

Bourbonne V, Vallières M, Lucia F et al (2019) MRI-derived radiomics to guide post-operative management for high-risk prostate cancer. Front Oncol 9:807. https://doi.org/10.3389/fonc.2019.00807

Article  PubMed  PubMed Central  Google Scholar 

Abdollahi H, Mofid B, Shiri I et al (2019) Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer. Radiol Med 124:555–567. https://doi.org/10.1007/s11547-018-0966-4

Article  PubMed  Google Scholar 

Jia Y, Quan S, Ren J et al (2022) MRI radiomics predicts progression-free survival in prostate cancer. Front Oncol 12:974257. https://doi.org/10.3389/fonc.2022.974257

Article  PubMed  PubMed Central